Financial Performance1Q24 total revenue of $1.8M was below estimates, and recurring software revenue of $1.6M was slightly below estimates.
Profitability TimelineThe company has pushed out its breakeven adjusted EBITDA target to 2026, from 2025.
Rating DowngradeZIVO Bioscience, Inc. downgraded to Hold due to capital constraints overshadowing potential feed deal with animal health company.